Today’s Research Reports on Stocks to Watch: TearLab and HTG Molecular Diagnostics

NEW YORK, NY / ACCESSWIRE / April 4, 2017 / TearLab fell 13.73% to close at $2.45 on Monday. The stock traded between $2.40 and $2.91 on volume of 630,182 shares traded. The company reported its 4th quarter and year-end financial results. It reported total 2016 revenues of $28 million, which is an increase of 11% when compared to revenues of $25.2 million a year ago.

TearLab received a CE Mark approval for its next generation platform in March, which results in regulatory clearance to market its products in the European Union and European Free Trade Association member countries. Other regulatory approvals included the Comisión Federal para la Protección contra Riesgos Sanitarios in Mexico and the Republic of Korea by the Ministry of Health and Welfare. Its TearLab Osmolarity System was made available in the Republic of India through its international partner, My HealthSkape PVT Ltd.

Access RDI’s TearLab Research Report at: https://ub.rdinvesting.com/news/?ticker=TEAR

HTG Molecular Diagnostics dropped 9.39% to close at $6.27 on Monday. The stock traded between $6.21 and $6.83 on volume of 1.7 million shares traded. The company had announced its 4th quarter and 2016 full year financial report on March 23rd of this year. It posted an operating loss of $24.3 million, an increase of $5.8 million from the previous year.

Access RDI’s HTG Molecular Research Report at: https://ub.rdinvesting.com/news/?ticker=HTGM

Our Actionable Research on TearLab Corp. (NASDAQ: TEAR) and HTG Molecular Diagnostics Inc. (NASDAQ: HTGM) can be downloaded free of charge at Research Driven Investing.

RDI Initiates
Coverage on:

TearLab Corp. https://ub.rdinvesting.com/news/?ticker=TEAR

HTG Molecular
Diagnostics Inc. https://ub.rdinvesting.com/news/?ticker=HTGM

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458932